Navigation Links
BioNeutral Group Appoints A New Member to the Board of Directors
Date:6/29/2012

NEWARK, N.J., June 29, 2012 /PRNewswire/ -- BioNeutral Group Inc. (OTCBB: BONU) a specialty life science technology based company announced today expansion of its Board of Directors. Michael D. Francis, J. D. has been newly appointed to the Board of Directors.

Mr. Francis is a graduate of the Wharton School of Business, University of Pennsylvania and received his Juris Doctorate from Rutgers University, School of Law. He has been admitted as an attorney in the state of New Jersey since 1971. Throughout his career, Mr. Francis has held numerous board appointments within the health care industry. From 1978 to present, he has been Director of the Daughters of Israel Geriatric Center, and held former posts as its Treasurer, President and Vice President.  Previously, Mr. Francis was Chairman of Board for the following organizations: Newark Beth Israel Medical Center from 1980 to 1998; United Way of Essex and West Hudson from 1986 to 1990; and Beth Health Care Foundation from 1988 to 1999. His executive management experience includes Chairman and CEO of the Planned Companies from 1989 to 2008 and President of All State Cleaning Contractors from 1971 to 1985. He was CEO of Atlantic Building Maintenance Corp. from 1971 to 1985, where he was responsible for managing the aforementioned companies, providing multifaceted building maintenance services with in excess of 1,000 employees.   Mr. Francis was responsible for executing the Sale of both Planned Companies and Atlantic Building Maintenance Company in multi-million dollar transaction. Mr. Francis is a principal stockholder of the Company.

Dr. Andy Kielbania stated: "We welcome Mr. Francis to BioNeutral's Board of Directors and are pleased to have the seasoned entrepreneurial experience of Michael Francis assisting our company.  Mr. Francis is a principal stockholder of the Company who has invested his own money into the Company and accordingly shares the interests of our stockholders."

About BioNeutral Group Inc.

Headquartered in Morristown, New Jersey with lab facilities at the New Jersey Institute of Technology in Newark, Inc., is a specialty technology-based life-science company which has developed a technology platform that neutralizes harmful environmental contaminants, toxins and dangerous micro-organisms including bacteria, viruses, mold, fungi and spores. BioNeutral's products, Ygiene® and Ogiene®, kill germs and clean surfaces with a dramatic increase in speed and power over their rivals in the marketplace. BioNeutral's proprietary platform technology has been proven effective in surface, water and airborne applications. Its antimicrobial line of products under the Ygiene® brand have been approved by the EPA for sale in the United States and has previously been approved for sale in Germany and it is also permitted to be sold in the UK, France and Sweden. Auto Neutral is a registered trademark of BioNeutral Group, Inc. For more information on BioNeutral, including a listing of company products, leadership and background please visit www.bioneutral.com.  

Find us on Facebook: http://www.facebook.com/pages/BioNeutral-Group/149109938452393  

Follow us on Twitter: http://twitter.com/bioneutralgroup  

Forward-Looking Statements: This release contains certain "forward-looking statements" relating to the business of the Company and its subsidiary companies. These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those described in the Company's filings with the Securities and Exchange Commission. BioNeutral routinely tests its formulations against those of its competitors. The results are published to let shareholders know how the Company's technology compares with known formulations in the market place. Any product claim for antimicrobial activity requires approval from the EPA or FDA, depending upon where and how the formulations are used. The EPA has approved and registered the Company's data and findings specific to Ygiene-206. BioNeutral's antimicrobial formulations will be marketed under the brand name Ygiene® and are available for sale in the United States.


'/>"/>
SOURCE BioNeutral Group Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. BioNeutral Group Receives $400,000 in Equity Financing
2. Foundation Venture Capital Group Makes Eighth Start-Up Investment
3. Hark! Group demonstrates first heralded single photon source made from silicon
4. Butamax Early Adopters Group surpasses capacity targets with addition of Big River; Membership represents 11 production facilities and nearly 900 million gallons of ethanol capacity
5. aTyr Pharma Receives Industry Innovation Awards from TiE and San Diego Venture Group
6. Nitor Group Demonstrates Direct Product Suite at Direct Implementation and Adoption Summit May 31-June 1
7. Mindray Renews Agreement with HealthTrust Purchasing Group, L.P. to Provide Patient Monitoring Equipment
8. Phalanx Biotech Group Announces CytoOneArray®, a Targeted Chromosomal Microarray
9. MiMedx Group Announces Record First Quarter Results
10. SOCMA Announces Launch of SCD-iBIO Group
11. AMRI Strengthens Business Development and Marketing Groups
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... Georgia (PRWEB) , ... December 05, 2016 , ... ... lignin-coated nanocellulose, including both cellulose nanocrystals and cellulose nanofibrils. The composition claims ... There are also claims directed to combination with polymers, carbon fibers, graphene, ...
(Date:12/5/2016)... 5, 2016  Renova™ Therapeutics, a biotechnology company ... and other chronic diseases, announced that Catherine ... Chief Financial Officer (CFO), effective today. ... of experience in financial management for a variety ... companies. Most recently, Ms. Bovenizer was the Vice ...
(Date:12/5/2016)... NEW YORK , December 5, 2016 ... Biotech player worldwide, with almost $108 billion of revenue ... around $170 billion were spent on global biopharmaceuticals, and ... 2017. This morning, Stock-Callers.com has lined up these four ... NWBO ), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... soon resume cervical and lumbar disc production, company President, Jake Lubinski will be ... are implanting the AxioMed disc in Bern, Lucerne, and Zurich to discuss the ...
Breaking Biology Technology:
(Date:11/30/2016)... Nov. 30, 2016  higi SH llc (higi) ... initiative targeting national brands, industry thought-leaders and celebrity ... respective audiences for taking steps to live healthier, ... in 2012, higi has built the largest self-screening ... 38 million people who have conducted over 185 ...
(Date:11/24/2016)... , Nov. 23, 2016 Cercacor today ... athletes and their trainers non-invasively measure hemoglobin, ... Pulse Rate, and Respiration Rate in approximately 30 seconds. ... users easy and immediate access to key data about ... of a training regimen. Hemoglobin carries ...
(Date:11/17/2016)... Market Watch: Primarily supported by ownership types; Private ... market is to witness a value of US$37.1 billion by ... Annual Growth Rate (CAGR) of 10.75% is foreseen from ... North America is not way behind ... at 9.56% respectively. Report Focus: The ...
Breaking Biology News(10 mins):